Oruka Therapeutics Inc. is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka Therapeutics Inc., formerly known as ARCA biopharma Inc., is based in WESTMINSTER, Colo.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-83.72M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -25.66% |
| Return on Assets (Trailing 12 Months) | -23.39% |
| Current Ratio (Most Recent Fiscal Quarter) | 30.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 30.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.84 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.40 |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.44M |
| Free Float | 28.20M |
| Market Capitalization | $448.16M |
| Average Volume (Last 20 Days) | 0.15M |
| Beta (Past 60 Months) | -0.38 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 24.69% |
| Percentage Held By Institutions (Latest 13F Reports) | 56.44% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |